Compare CCS & SNDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CCS | SNDX |
|---|---|---|
| Founded | 2000 | 2005 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Homebuilding | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.9B | 1.7B |
| IPO Year | 2014 | 2016 |
| Metric | CCS | SNDX |
|---|---|---|
| Price | $60.30 | $19.53 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 5 | 12 |
| Target Price | ★ $70.50 | $36.92 |
| AVG Volume (30 Days) | 240.3K | ★ 2.3M |
| Earning Date | 01-28-2026 | 11-03-2025 |
| Dividend Yield | ★ 1.92% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 6.93 | N/A |
| Revenue | ★ $4,157,669,000.00 | $111,304,000.00 |
| Revenue This Year | N/A | $620.14 |
| Revenue Next Year | $8.74 | $115.42 |
| P/E Ratio | $8.73 | ★ N/A |
| Revenue Growth | N/A | ★ 595.65 |
| 52 Week Low | $50.42 | $8.58 |
| 52 Week High | $88.41 | $20.59 |
| Indicator | CCS | SNDX |
|---|---|---|
| Relative Strength Index (RSI) | 45.91 | 61.91 |
| Support Level | $63.69 | $18.36 |
| Resistance Level | $67.10 | $20.59 |
| Average True Range (ATR) | 2.10 | 0.99 |
| MACD | -0.03 | 0.05 |
| Stochastic Oscillator | 38.97 | 73.22 |
Century Communities Inc is engaged in the development, design, construction, marketing, and selling of single-family attached and detached homes. It has five homebuilding segments: West, Mountain, Texas, Southeast, and Century Complete. Its sixth reportable segment is financial services operations, which provides mortgage, title, and insurance services to homebuyers. It has acquired land for homebuilding operations with the primary intent to develop and construct single-family detached or attached homes for sale on the acquired land. The company sells homes through its sales representatives and independent real estate brokers. The company generates the majority of its revenue from the Mountain segment.
Syndax Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing a pipeline of combination therapies in multiple cancer indications. Its product candidates include revumenib and axatilimab. It is developing revumenib, a selective menin-MLL inhibitor for KMT2A-rearranged (MLL-r) and NPM1-mutant acute leukemias, including ALL and AML. It is also developing axatilimab, a CSF-1R-blocking antibody for cGVHD and idiopathic pulmonary fibrosis. Entinostat is its oral, small molecule product candidate that has direct effects on both cancer cells and immune regulatory cells. The business activity of the group is functioned through the region of the United States.